Mallinckrodt LLC
252 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 16 name spellings.
Recorded as renamed to MNK 2011 (2023)
Recorded as renamed to Mallinckrodt IP Unlimited Company (2018)
6
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 30, 2027The maintenance fee for (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof (US 10,363,251) comes due Jan 30, 2027. Unpaid by Jul 30, 2027, it lapses early.
- 1 fee due Apr 15, 2027The maintenance fee for Systems and Methods for High Humidity Curing Within Tablet Coating System (US 10,441,508) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 2 fees due May 17 to 26, 2027 · next May 17
- 2 fees due Sep 15 to 30, 2027 · next Sep 15
- 1 fee due Oct 21, 2027The maintenance fee for Extended Release, Abuse Deterrent Dosage Forms (US 10,624,888) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
- 8 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,562,014 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,363,251 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 10,604,488 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 9,856,251 | Substituted Berbines and Processes for Their Synthesis In force · High confidence | In force | High confidence | |
| US 9,186,349 | Diaza Heterocyclic Compounds for Phototherapy In force · High confidence | In force | High confidence | |
| US 11,142,502 | (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,285,487 | Systems and Methods for Assaying an Eluate for Technetium and Molybdenum Content In force · High confidence | In force | High confidence | |
| US 10,485,753 | Extended Release, Abuse Deterrent Pharmaceutical Compositions In force · High confidence | In force | High confidence | |
| US 9,895,484 | Injector System In force · High confidence | In force | High confidence | |
| US 10,157,263 | Contrast Media Injection Data Management In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 252 patents in force now held by others · 263 lapsed for an unpaid fee · 641 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
78 abandoned · 35 no status recorded